Vaxgen (Anthrax Vaccine Assets and Technology) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Vaxgen (Anthrax Vaccine Assets and Technology) General Information

Description

Anthrax vaccine program and related assets and technology. The portfolio includes all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Acquirer
Emergent Biosolutions
Primary Office
  • 349 Oyster Point Boulevard
  • Suite 10
  • South San Francisco, CA 94080
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaxgen (Anthrax Vaccine Assets and Technology) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vaxgen (Anthrax Vaccine Assets and Technology)‘s full profile, request access.

Request a free trial

Vaxgen (Anthrax Vaccine Assets and Technology) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vaxgen (Anthrax Vaccine Assets and Technology)‘s full profile, request access.

Request a free trial